REMARKS

Claims 1, 3, 8-22, 26, 27, 29, 30, 34-38, 40, 44-51 and 54-65 are pending.

Applicant has cancelled, without prejudice, Claims 11-13, 44-46 and 48-51.

Applicant has amended independent Claims 1, 17, 26 and 34 without prejudice with respect to any material no longer encompassed by the newly amended claims. These claim amendments further clarify the claimed invention by specifying that the claimed formulation is free of additional active components. Support for this amendment is found throughout the specification, particularly in paragraphs 50 and 55 of the published specification, where it is disclosed that "formulations of PACAP 66 may be used alone". No new matter has been added as a result of the amendments.

Applicant has further amended Claims 1 and 34, to specify that the zinc salt is $ZnCl_2$. Applicant has amended Claims 15 and 16, which previously depended from claim 11, to depend from Claim 1. Support for this amendment is found at least in the claims as originally filed.

Applicant submits that no new search is required as a result of these claim amendments.

35 U.S.C. § 102(e) - Edmondson

Claims 1, 3, 34-35, and 40 stand rejected under 35 U.S.C. 102(e) as being anticipated by Edmondson et al. (US Patent 7,125,873).

> "Anticipation requires that the purported prior art reference disclose each and every limitation of the claim". *Atlas Powder Company et al. v. IRECO, Incorporated et al.*, 190 F.3d 1342, 1347 (Fed. Cir. 1999).

Applicant respectfully traverses the rejection of the instant claims on the grounds that Edmondson et al. does not teach each and every limitation of the instant claims as newly amended.

Claim 1 and dependent claim 3, as newly amended, are drawn to a stabilized peptide formulation consisting essentially of the peptide PAP 66 or a salt thereof, a zinc salt, and a pharmaceutically acceptable organic solvent, where the zinc salt is $ZnCl_2$ and where the